This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Novum To Open State-of-the-Art Clinical Research Facility In Houston, TX

HOUSTON, April 5, 2013 /PRNewswire/ -- Novum Pharmaceutical Research Services, a leading contract research organization (CRO) serving the pharmaceutical industry in Phase I-Phase IV clinical trials and related services, announced today the opening of a new early-stage clinical facility in Houston, TX. The 55,000 square foot facility is scheduled to be operational in August, 2013.

"This exciting new facility reflects Novum's continued growth and our deep commitment to our clients' needs," said Christopher H. Chamberlain, Novum's Chief Executive Officer. "Like our other research facilities, it will provide a safe, convenient, and pleasant environment for our study participants," he added.

The GCP-compliant facility is being custom-built in Houston's Westchase district, a short distance from Novum's current clinics. The new facility will have seven research units that are designed to make the most efficient use of its 225 beds. Additionally, a 12-bed intensive monitoring unit will allow for early phase research studies requiring continuous cardiac and other specialized safety monitoring.  The floor plan and layout will provide a high degree of flexibility in space planning to handle multiple types of study designs. 

"While our employees and study participants truly make the difference at Novum, bringing this state-of-the-art facility online will raise the bar for Novum and the industry," said Dr. Darin Brimhall, Novum's Vice President of Clinic Operations.

About Novum PRS Novum is a contract research organization ("CRO") that provides Phase I through IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Founded in 1972, it operates Phase I research facilities with a total of 550 beds in three USA locations. Novum's expanding clinical trials management group currently focuses on performing Phase II through IV clinical endpoint studies requiring large patient numbers in ambulatory disease populations.  Visit http://www.novumprs.com for more information.

SOURCE Novum Pharmaceutical Research Services

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs